These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8911873)

  • 1. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Messori A; Bonistalli L; Costantini M; Trallori G; Tendi E
    J Clin Gastroenterol; 1996 Dec; 23(4):269-74. PubMed ID: 8957728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.
    Trippoli S; Becagli P; Messori A
    Eur J Clin Pharmacol; 1997; 53(3-4):281-2. PubMed ID: 9476047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
    Norum J
    Acta Oncol; 2000; 39(1):33-9. PubMed ID: 10752651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
    Chilcott J; Lloyd Jones M; Wilkinson A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
    Campbell HE; Epstein D; Bloomfield D; Griffin S; Manca A; Yarnold J; Bliss J; Johnson L; Earl H; Poole C; Hiller L; Dunn J; Hopwood P; Barrett-Lee P; Ellis P; Cameron D; Harris AL; Gray AM; Sculpher MJ
    Eur J Cancer; 2011 Nov; 47(17):2517-30. PubMed ID: 21741831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
    Norum J; Holtmon M
    Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
    Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
    Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.